Evercore ISI analyst Liisa Bayko lowered the firm’s price target on Editas Medicine (EDIT) to $5 from $7 and keeps an Outperform rating on the shares. Editas has decided to cut the reni-cel program following “a fruitless search for a commercial partner” and “fully morph into an in vivo gene editing company,” the analyst notes. There is “no clear front runner yet” who can unlock in vivo editing for sickle cell disease and Editas “has an equal shot to be a leader,” the analyst contends.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine downgraded to Underweight from Neutral at JPMorgan
- Editas Medicine downgraded to Hold from Buy at JonesResearch
- Salesforce upgraded, ServiceNow downgraded: Wall Street’s top analyst calls
- Editas Medicine price target lowered to $4 from $5 at RBC Capital
- Editas Medicine downgraded to Neutral from Buy at Chardan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
